Latest news with #drugmaker
Bloomberg
4 days ago
- Business
- Bloomberg
Indivior Plans to Cancel London Listing After Moving Primary to US
Indivior Plc said it plans to cancel its secondary listing in London nearly a year after the drugmaker shifted its primary trading to the US, marking the latest departure from the UK's capital markets. The opioid-addiction therapy maker moved its main listing to New York last year in search of more analyst and investor coverage, but had a rocky start amid guidance cuts. It's planning to ditch the secondary trading it had maintained on the London Stock Exchange to better reflect where its revenues come from and eliminate the cost of the secondary listing, given most of its volume and investors are now in the US, according to a statement.
Reuters
29-05-2025
- Business
- Reuters
US cancels over $700 mln funding for Moderna bird flu vaccine
The Trump administration has canceled a contract awarded to Moderna for the late-stage development of its bird flu vaccine for humans, as well as the right to purchase shots, the drugmaker announced on Wednesday. Julian Satterthwaite reports.
Reuters
22-05-2025
- Business
- Reuters
India's Sun Pharma posts quarterly profit rise on strong demand for rare disease drugs
May 22 (Reuters) - Sun Pharmaceutical ( opens new tab, India's largest drugmaker by revenue, reported a rise in adjusted quarterly profit on Thursday, driven by strong domestic demand for its drugs to treat rare diseases. The Mumbai-based firm's consolidated profit before exceptional items and tax rose 24% to 36.16 billion rupees ($420.7 million) in the three months ended March 31. ($1 = 85.9500 Indian rupees)
Bloomberg
09-05-2025
- Business
- Bloomberg
Sarepta's Week Goes From Bad to Worse on FDA Fears, Outlook Cut
Sarepta Therapeutics Inc. is on pace for its worst week in four years as disappointing earnings and regulatory fears hit the drugmaker's shares. The pain started Tuesday, when Sarepta sank 27% after the commissioner for the Food and Drug Administration named a new regulator that was seen as a vocal critic of the company and its lead medicine, Elevidys. Then, the Cambridge, Massachusetts-based firm cut its net product revenues forecast for the full year, following disappointing sales for the first quarter. Shares extended their losses by another 21% on Wednesday.
Bloomberg
07-05-2025
- Business
- Bloomberg
Shionogi Falls on Report of $1 Billion Offer to Buy Torii Pharma
Shares of Japanese drugmaker Shionogi & Co. dropped the most in almost a month after the Nikkei newspaper reported the company will buy Torii Pharmaceutical Co. for about ¥150 billion ($1 billion). The acquisition will include buying a stake from Japan Tobacco Inc., which owns about 53% of Torii, through a tender offer and other means, the newspaper said Wednesday, without citing where it obtained the information.
